EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

Irene Strassl iD, Alexander Nikoloudis, Lina Zoe Ruesing iD, Thomas Melchardt iD, Michael Leisch, Eduard Schulz iD, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler-Izmir und 12 weitere

British Journal of Haematology · 2026-11 · 209 (5) · 2180-2190

DOI: 10.1111/bjh.70773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 26.08.2026. Verfasst von Irene Strassl und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I: Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen,…. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Biological Products. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and toxicity. We performed a nationwide retrospective real‐world analysis (RWA) of Austrian patients treated with ide‐cel or cilta‐cel between January 2024 and July 2025. Ninety patients were included, with largely balanced baseline characteristics and frequent high‐risk features. Bridging therapy was administered to 94.4% of patients, resulting in high response rates prior to lymphodepletion. After a median follow‐up of 17.6 months, no early separation of the progression‐free survival (PFS) curves was observed between CAR‐T products. Multivariable analyses showed a trend towards improved PFS with cilta‐cel, whereas true extra‐medullary disease (EMD) and prior bispecific antibody treatment before T‐cell apheresis were associated with inferior PFS. Although previous RWA have demonstrated an early divergence in PFS between cilta‐cel and ide‐cel, this pattern was not observed in our cohort. The high effectiveness of bridging therapy may have contributed to these findings. Our results support further investigation of optimal bridging strategies and treatment sequencing while highlighting the persistent unmet need of patients with true EMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveBiological ProductsHumansRetrospective StudiesFemaleAustriaMaleAgedMiddle AgedTreatment OutcomeRecurrenceAged, 80 and overReceptors, Chimeric Antigen

Stichwörter der Autor:innen

CAR‐Tmyelomareal‐world analysis

Substanzen

idecabtagene vicleucelBiological ProductsReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Internal Medicine I: Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria.
  • Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
  • Bone Marrow Transplantation Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Internal Medicine III With Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Clinical Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Irene Strassl, Lina Zoe Ruesing, Thomas Melchardt, Eduard Schulz, Johannes Clausen, Veronika Buxhofer-Ausch, Sigrid Machherndl-Spandl, Nina Worel, Hermine Agis

Zitieren

APA

Strassl, I., Nikoloudis, A., Ruesing, L. Z., Melchardt, T., Leisch, M., Schulz, E., Heine, A., Neumeister, P., Steiner, N., Wolf, D., Willenbacher, W., Pichler-Izmir, P., Lentner, T., Clausen, J., Buxhofer-Ausch, V., Machherndl-Spandl, S., Saini, O., Wipplinger, D., Rumpold, H., …, & Krauth, M. T. (2026). Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria. British Journal of Haematology, 209(5), 2180-2190. https://doi.org/10.1111/bjh.70773

Vancouver

Strassl I, Nikoloudis A, Ruesing LZ, Melchardt T, Leisch M, Schulz E, et al. Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria. British Journal of Haematology. 2026;209(5):2180-2190. doi:10.1111/bjh.70773

BibTeX
@article{Strassl2026,
  author = {Strassl, Irene and Nikoloudis, Alexander and Ruesing, Lina Zoe and Melchardt, Thomas and Leisch, Michael and Schulz, Eduard and Heine, Annkristin and Neumeister, Peter and Steiner, Normann and Wolf, Dominik and Willenbacher, Wolfgang and Pichler-Izmir, Petra and Lentner, Theresa and Clausen, Johannes and Buxhofer-Ausch, Veronika and Machherndl-Spandl, Sigrid and Saini, Olga and Wipplinger, Dagmar and Rumpold, Holger and Worel, Nina and Rabitsch, Werner and Schulenburg, Axel and Agis, Hermine and Krauth, Maria-Theresa},
  title = {Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2180--2190},
  doi = {10.1111/bjh.70773}
}
Kostenlos starten →